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Reversal of oxycodone and hydrocodone tolerance by 
diazepam 
Maciej Goneka Hamid I. Akbaralia Graeme Hendersonb William L. Deweya 
Highlights 
Antinociceptive tolerance developed to oxycodone and hydrocodone. 
• 
0.5 mg/kg diazepam fully reversed antinociceptive tolerance to 
oxycodone. 
• 
2 mg/kg diazepam fully reversed antinociceptive tolerance to 
hydrocodone. 
• 
There was no potentiation of acute opioid antinociceptive effects by 
diazepam. 
• 
Oxycodone locomotor tolerance was reversed by 0.5 mg/kg 
diazepam. 
Abstract 
The Centers for Disease Control has declared opioid abuse to be an epidemic. 
Overdose deaths are largely assumed to be the result of excessive opioid 
consumption. In many of these cases, however, opioid abusers are often 
polydrug abusers. Benzodiazepines are one of the most commonly co-abused 
substances and pose a significant risk to opioid users. In 2016, the FDA 
required boxed warnings – the FDA’s strongest warning – for prescription 
opioid analgesics and benzodiazepines about the serious risks associated with 
using these medications at the same time. The point of our studies was to 
evaluate the interactions between these two classes of drugs. We investigated 
whether diazepam adds to the depressant effects of opioids or do they alter the 
levels of tolerance to opioids. In the present study, we have found that the 
antinociceptive tolerance that developed to repeated administration of 
oxycodone was reversed by an acute dose of diazepam. Antinociceptive 
tolerance to hydrocodone was also reversed by acute injection of diazepam; 
however, a fourfold higher dose of diazepam was required when compared to 
reversal of oxycodone-induced tolerance. These doses of diazepam did not 
potentiate the acute antinociceptive effect of either opioid. The same dose of 
diazepam that reversed oxycodone antinociceptive tolerance also reversed 
oxycodone locomotor tolerance while having no potentiating effects. These 
studies show that diazepam does not potentiate the acute effect of prescription 
opioids but reverses the tolerance developed after chronic administration of the 
drugs. 
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1. Introduction 
Reducing opioid overdose deaths is an important public health and drug policy 
goal. Much of the current opioid epidemic can be attributed to the rise in use of 
prescription opioid pain analgesics such as oxycodone and hydrocodone. 
These drugs have become widely prescribed, with enough opioid analgesics 
sold in 2010 to medicate every American adult with a typical dose every 4 h for 
1 month. The CDC reported that in the United States, at least half of all opioid 
overdose deaths involve a prescription opioid (Paulozzi et al., 2011). 
The dangers of accidental opioid overdose are mainly due to respiratory 
depressive effects. Chronic use of opioids results in the development of 
tolerance (a decrease in pharmacologic response following repeated or 
prolonged drug administration) to the analgesic, euphoric, and respiratory 
depressive effects. This leads to addicts and patients taking higher doses in 
order to obtain the euphoric high or the analgesic effects, respectively. 
However, it has been shown that tolerance to different effects of opioids do not 
occur at the same rate or to the same extent (Hill et al., 2016). It has been 
suggested that, in man, tolerance to euphoriadevelops to a greater extent than 
to respiratory depression (White and Irvine, 1999). 
Opioid overdose deaths are largely assumed to result from excessive opioid 
administration alone. However, opioid abusers are often polydrug users, 
consuming benzodiazepines, ethanol, cocaine and/or gabapentoids along with 
opioid drugs. Benzodiazepines and ethanol have been found to pose a 
significant risk to chronic opioid users, particularly in those 
taking methadone (National Treatment Agency and for Substance Misuse 
[NTA], 2007). The CDC has reported that benzodiazepines were involved in 
31% of opioid related drug poisoning deaths in recent years (Chen et al., 2014). 
Benzodiazepines, ethanol, and opioids are all considered central nervous 
system depressants and their effects may be additive or synergistic. Recently, 
our lab has published that low doses of ethanol and diazepam, which have no 
observable effect of their own, significantly and dose-dependently reduced 
the antinociceptive tolerance produced by morphine while not affecting the 
acute responses (Hull et al., 2013). Low doses of ethanol reversed morphine 
tolerance at the level of single brain neurons (Llorente et al., 2013) and in a 
rodent model of respiratory depression (Hill et al., 2016). 
A major limitation of the previously described studies is that they have not 
investigated oxycodone and hydrocodone, two commonly prescribed opioid 
analgesics. Limited research has been done with these drugs when compared 
to the opioid standard, morphine, and the illicit compound heroin. Although all 
are considered opioids, these compounds may differently interact through the 
μ opioid receptor (MOR). They have been shown to have 
different pharmacokinetic properties, varying affinities for the μ opioid receptor, 
potentially interact with other opioid receptors and have different off-target 
effects (Nielsen et al., 2007). Therefore, it is important to investigate how 
commonly prescribed opioids compare in their effects to morphine. 
The goals of this study were to determine if benzodiazepines potentiate the 
acute antinociceptive effects of commonly prescribed opioids as well as to 
determine if they act to reduce tolerance to these opioids. We characterized the 
development of antinociceptive tolerance to oxycodone and hydrocodone in 
mice and investigated whether diazepam could reverse tolerance as it does 
morphine-induced tolerance. Antinociception, as measured by the rodent warm 
water tail-immersion assay, was chosen for these studies because it has been 
shown to be a good predictor of antinociception and tolerance for a wide range 
of compounds in humans. Furthermore, our group has used this assay to 
extensively investigate the mechanisms of opioid tolerance (Hull et al., 2013, 
2010; Smith et al., 2007). 
2. Results 
2.1. Effects of acute diazepam in drug-naïve mice 
Diazepam was administered at doses of 0.5, 1, and 2 mg/kg i.p. and mice were 
monitored over a 3-h period for behavioral changes and assessed in the warm-
water tail immersion test at 30-min intervals over 2 h. No antinociceptive effects 
or behavioral changes, including locomotor activity, were observed at any of 
these doses. 
2.2. Tolerance development to oxycodone 
Baseline latencies were taken prior to the beginning of the hourly subcutaneous 
injections. Mice were randomly assigned to either a chronic saline or 
chronic opioid schedule whereby seven hourly injections of isotonic saline or an 
ED80 dose of oxycodone were given s.c. After seven injections, mice were 
injected with a challenge dose of oxycodone (0.25, 0.5, 1, 2 or 4 mg/kg) at the 
8-h time point (Fig. 1). Dose-response curves for oxycodone after chronic 
injections of saline generated similar ED50 values to those in acute dose 
response experiments (1.19 mg/kg (1.00–1.41, 95% CL)). The ED50 was 
significantly shifted to the right 1.6-fold, indicating tolerance was observed, in 
the animals chronically injected with oxycodone prior to receiving the challenge 
injections (1.84 mg/kg (1.58–2.14, 95% CL)). The sample size of each group 
was 20 animals [Acute Oxycodone, n = 20; Chronic Oxycodone, n = 20]. 
 
Fig. 1. Tolerance to oxycodone, developed using a single-day injection 
paradigm, was significantly reversed by 0.5 mg/kg diazepam (n = 10–20). 
Latency to tail withdrawal (% MPE ± SEM) among mice that were drug naïve, 
repeatedly treated with oxycodone, or repeatedly treated with oxycodone and 
diazepam pretreatment 30 min before testing. Various doses of the oxycodone 
were used for construction of dose-response curves for calculation of ED50 
values. 
2.3. Reversal of oxycodone antinociceptive tolerance with diazepam in tail 
immersion assay 
Baseline latencies were obtained in the tail immersion test in the morning 
before any injections. Following the development of tolerance (single day 
tolerance model), diazepam (0.5 mg/kg i.p.) was administered. Thirty minutes 
later, the mice were challenged with doses of oxycodone s.c. for construction of 
dose-response curves for calculation of the ED50values (Fig. 1; Table 1). 
Diazepam fully reversed the oxycodone-induced tolerance. The sample size of 
each group was between 10 and 20 animals [Acute Oxycodone, n = 20; 
Chronic Oxycodone, n = 20; Chronic Oxycodone + 0.5 mg/kg DZ, n = 12]. The 
same dose of diazepam did not potentiate the antinociception produced by 
acute doses of oxycodone in naive mice (Fig. 2) [Acute Oxycodone, n = 20; 
Acute Oxycodone + 0.5 mg/kg DZ, n = 11]. 
Table 1. Diazepam reversal of oxycodone tolerance. 
Treatment     Oxycodone ED50 (mg/kg (95% C.L.)) 
Acute Oxycodone + Vehicle    1.19 (1.00–1.41) 
Acute Oxycodone + Diazepam (0.5 mg/kg) 1.25 (1.04–1.50) 
Chronic Oxycodone + Vehicle   1.84 (1.58–2.14)* 
Chronic Oxycodone + Diazepam (0.5 mg/kg) 1.12 (0.88–1.43) 
*Significantly different than Acute Oxycodone + Vehicle group based on non-
overlapping 95%. 
 
Fig. 2. 0.5 mg/kg Diazepam did not potentiate the antinociception produced 
by oxycodone in the tail immersion test. (n = 10–20). Latency to tail withdrawal 
(% MPE ± SEM) among mice that were drug naïve or pretreated with diazepam 
30 min before testing. Various doses of the oxycodone were used for 
construction of dose-response curves for calculation of ED50 values. 
2.4. Tolerance development to hydrocodone 
Baseline latencies were taken prior to the beginning of hourly subcutaneous 
injections. Mice were assigned randomly to either a chronic saline or chronic 
opioid schedule whereby seven hourly injections of isotonic saline or an 
ED80 dose of hydrocodone were given s.c. After seven injections, all mice were 
injected with final challenge doses of hydrocodone (1, 2, 4, 8, 16 or 32 mg/kg) 
at the 8-h time point (Fig. 3). Dose response curves of hydrocodone after 
chronic injections of saline generated similar ED50 values to those in acute 
dose response experiments (5.51 mg/kg (4.97–6.12, 95% CL)). The ED50 was 
significantly shifted 2.4-fold to the right in the animals chronically injected with 
hydrocodone prior to receiving the challenge injections (13.18 mg/kg (11.00–
15.80, 95% CL)). The sample size of each group was between 6 and 12 
animals [Acute Hydrocodone, n = 6; Chronic Hydrocodone, n = 12]. 
 
Fig. 3. 0.5 mg/kg Diazepam did not fully reverse the antinociception produced 
by hydrocodone in the tail immersion test (n = 6–12). Latency to tail withdrawal 
(% MPE ± SEM) among mice that were drug naïve, repeatedly treated with 
hydrocodone, or repeatedly treated with hydrocodone and pretreated with 
diazepam 30 min before testing. Various doses of the hydrocodone were used 
for construction of dose-response curves for calculation of ED50 values. 
2.5. Reversal of hydrocodone antinociceptive tolerance with diazepam in tail 
immersion assay 
Baseline latencies were obtained in the tail immersion test in the morning 
before any injections. Following the development of tolerance (single day 
tolerance model), diazepam was administered i.p. Thirty minutes later, the mice 
were challenged with doses of hydrocodone s.c. for construction of dose-
response curves for calculation of the ED50 values (Table 2). In contrast with 
oxycodone, 0.5 mg/kg diazepam did not fully reverse antinociceptive tolerance 
to hydrocodone (Fig. 3). 2 mg/kg diazepam fully reversed hydrocodone 
tolerance and actually significantly potentiated the antinociceptive effect of 
hydrocodone after chronic administration (Fig. 4). However, 2 mg/kg diazepam 
did not potentiate the antinociception produced by an acutely administered 
dose of hydrocodone (Fig. 5). The sample size of each group was between 6 
and 12 animals [Fig. 3: Acute Hydrocodone, n = 6; Chronic Hydrocodone, 
n = 12; Chronic Hydrocodone + 0.5 mg/kg DZ n = 8; Fig. 4: Acute 
Hydrocodone, n = 12; Chronic Hydrocodone, n = 12; Chronic 
Hydrocodone + 2 mg/kg DZ n = 6; Fig. 5: Acute Hydrocodone, n = 12; Acute 
Hydrocodone + 2 mg/kg DZ n = 6]. 
Table 2. Diazepam reversal of hydrocodone tolerance. 
Treatment Hydrocodone   ED50 (mg/kg (95% C.L.)) 
Acute Hydrocodone + Vehicle   5.51 (4.97–6.12) 
Acute Hydrocodone + Diazepam (2 mg/kg) 4.48 (3.22–6.25) 
Chronic Hydrocodone + Vehicle   13.18 (11.00–15.80)* 
Chronic Hydrocodone + Diazepam (0.5 mg/kg) 9.92 (7.74–12.70)* 
Chronic Hydrocodone + Diazepam (2 mg/kg) 3.77 (2.83–5.04) 
* 
Significantly different than Acute Hydrocodone + Vehicle group based on non-
overlapping 95%. 
 
Fig. 4. 2 mg/kg Diazepam fully reversed the antinociception produced 
by hydrocodone in the tail immersion test (n = 6–12). Latency to tail withdrawal 
(% MPE ± SEM) among mice that were drug naïve, repeatedly treated with 
hydrocodone, or repeatedly treated with hydrocodone and pretreated with 
diazepam 30 min before testing. Various doses of the hydrocodone were used 
for construction of dose-response curves for calculation of ED50 values. 
 
Fig. 5. 2 mg/kg Diazepam did not potentiate the antinociception produced 
by hydrocodone in the tail immersion test (n = 6–12). Latency to tail withdrawal 
(% MPE ± SEM) among mice that were drug naïve or pretreated with diazepam 
30 min before testing. Various doses of the hydrocodone were used for 
construction of dose-response curves for calculation of ED50 values. 
2.6. Reversal of oral oxycodone antinociceptive tolerance with diazepam in tail 
immersion assay 
Following the development of maximum tolerance (4-day oral tolerance model), 
diazepam was administered i.p. Thirty minutes later, the mice were challenged 
with doses of oxycodone p.o. for construction of dose-response curves for 
calculation of the ED50 values. The ED50 of the acute oral oxycodone was 8.33 
(5.77–12.03, 95% CL). There was marked tolerance to oral oxycodone 
following the 4-day oral tolerance model. The observation that 0.5 mg/kg 
diazepam was able to fully reverse the antinociceptive tolerance to oral 
oxycodone (Fig. 6) was supported by the overlapping ED50: 13.24 mg/kg (4.00–
43.93, 95% CL). Administering 0.5 mg/kg diazepam to animals given acute oral 
oxycodone generated the ED50 value of 7.27 mg/kg (5.01–10.54, 95% CL), 
indicating that it did not potentiate the antinociception produced by acute doses 
of oxycodone (Fig. 7). The sample size of each group was between 6 and 7 
animals [Fig. 6: Acute Oral Oxycodone, n = 6; Chronic Oral Oxycodone, n = 7; 
Chronic Oral Oxycodone + 0.5 mg/kg DZ n = 6; Fig. 7: Acute Oral Oxycodone, 
n = 6; Acute Oral Oxycodone + 2 mg/kg DZ n = 6]. 
 
Fig. 6. 0.5 mg/kg Diazepam fully reversed the antinociception produced by 
multiple-day paradigm of oral oxycodone in the tail immersion test. (n = 6–7). 
Latency to tail withdrawal (% MPE ± SEM) among mice that were drug naïve, 
repeatedly gavaged with oxycodone over 4 days, or repeatedly gavaged with 
oxycodone over 4 days and pretreated with diazepam 30 min before testing. 
Various doses of the oxycodone were used for construction of dose-response 
curves for calculation of ED50 values. 
 
Fig. 7. 0.5 mg/kg Diazepam did not potentiate the antinociception produced 
by oxycodone (p.o.) in the tail immersion test (n = 6). Latency to tail withdrawal 
(% MPE ± SEM) among mice that were drug naïve or pretreated with diazepam 
30 min before testing. Various doses of the oxycodone were used for 
construction of dose-response curves for calculation of ED50 values. 
2.7. The lack of the development of antinociceptive tolerance to oral 
hydrocodone in tail immersion assay 
We attempted a model to produce tolerance to oral hydrocodone in the tail 
immersion assay. A dose response curve of acute oral hydrocodone was 
established and reliably repeated. However, we did not succeed in developing 
tolerance to oral gavages of hydrocodone (data not shown). Methods to 
establish such a model included a 4-day antinociceptive tolerance model using 
a twice a day dosing schedule of 32, 64, 128, or 256 mg/kg. 
2.8. Development of locomotor tolerance to oral oxycodone and subsequent 
reversal with diazepam 
Tolerance was examined by assessing changes of locomotor activity after 
acute and repeated oxycodone gavages. A main effect was noted for treatment 
group [F(3,15) = 5.49, p < 0.001], time [F(7,105) = 10.89, p < 0.0001], and 
treatment × time interaction [F(21,105) = 4.29, p < 0.001]. Post hoc tests 
demonstrated acutely administered 64 mg/kg oral oxycodone produced 
significant increased ambulatory counts starting from 20 min (with the exception 
at the 25-min time point) until the 40-min endpoint (Fig. 8). Using a modified 4-
day oral tolerance model, tolerance to morphine’s stimulatory effects was 
observed. After the administration of 0.5 mg/kg diazepam to mice that were 
repeatedly treated with oral oxycodone, 64 mg/kg oral oxycodone produced 
significant increased ambulatory counts starting from the 35-min time point until 
the 40-min endpoint. In determining the effects of acute diazepam by itself or 
on acute oxycodone’s stimulatory effects, a two-way ANOVA revealed a main 
effect for treatment group [F(3,16) = 9.37, p < 0.001], time [F(7,112) = 34.62, 
p < 0.0001], and treatment × time interaction [F(21,112) = 10.42, p < 0.001]. Post 
hoc tests revealed that 0.5 mg/kg diazepam did not potentiate acute 
oxycodone’s stimulatory effects in the locomotor assay. This dose of diazepam 
did not show any stimulatory effects on its own (Fig. 9). The sample size of 
each group was five animals with the exception of the chronic morphine group 
with four animals. 
 
Fig. 8. Locomotor stimulation in response to vehicle or oxycodone (64 mg/kg 
p.o.) was assessed (n = 5). * Indicates a significant effect of acute oxycodone 
increasing ambulatory counts as compared to mice naïve to the opioid (treated 
with vehicle). † Indicates a significant effect of chronic 
oxycodone + 0.5 mg/kg diazepam increasing ambulatory counts as compared 
to mice naïve to the opioid (p < 0.05). 
 
Fig. 9. Locomotor stimulation in response to vehicle, diazepam (0.5 mg/kg i.p.) 
or oxycodone (64 mg/kg p.o.) was assessed (n = 5). * Indicates a significant 
effect of both acute oxycodone and acute oxycodone + 0.5 mg/kg diazepam 
increasing ambulatory counts as compared to mice naïve to 
the opioid(p < 0.05). 0.5 mg/kg diazepam does not potentiate acute 
oxycodone’s stimulatory effects. 0.5 mg/kg diazepam does not produce a 
difference in stimulatory counts when compared to naïve controls. 
3. Discussion 
Oxycodone and hydrocodone remain among the most commonly prescribed 
drugs for relief of acute and chronic pain. However, tolerance limits the long-
term utility of these opioid agonists, leading to escalating doses of opioids to 
achieve the same analgesic effect while increasing the risks for abuse liability 
and death from respiratory depression. Additionally, people who become 
tolerant and then addicted to opioids usually are consuming other substances 
as well. Therefore, it is imperative to investigate the effects of these other 
substances on opioid tolerance. In this study, we investigated the effects 
of diazepam, a widely coabused substance, on oxycodone and 
hydrocodone antinociceptive tolerance and oxycodone locomotor stimulating 
tolerance in mice. 
We found that diazepam reversed the antinociceptive tolerance that developed 
after repeated injections of subcutaneous oxycodone. The observation that an 
acute dose of diazepam, that was inactive alone, reversed tolerance to the 
antinociceptive effects of oxycodone is in agreement with our previous studies 
in which we demonstrated that diazepam reversed tolerance to the 
antinociceptive effects of morphine (Hull et al., 2013). We also demonstrated 
that the same dose of diazepam that reversed oxycodone tolerance did not 
significantly enhance the antinociceptive effect of acute oxycodone. 
Patients are often administered oxycodone in tablets or solutions intended for 
oral use. Therefore, in a separate series of experiments, we investigated the 
ability of diazepam to reverse maximum tolerance of oral oxycodone. In these 
studies, to achieve that maximum tolerance, we administered 256 mg/kg 
oxycodone orally twice a day for four days. Testing on the fifth day, this protocol 
produced significant tolerance illustrated by the lack of effective doses as high 
as 64 mg/kg. The observation that 0.5 mg/kg diazepam was able to reverse this 
maximum tolerance further supports the phenomenon of oxycodone tolerance 
reversal by benzodiazepines. 
Furthermore, we found that diazepam reversed the antinociceptive tolerance 
that developed after repeated subcutaneous injections of hydrocodone. 
However, the reversal of tolerance to hydrocodone required a larger dose of 
diazepam than needed to reverse oxycodone or morphine tolerance. It is clear 
that diazepam did not potentiate the acute antinociceptive effect of 
hydrocodone. Further investigation is needed into why diazepam reversed 
oxycodone and morphine antinociceptive tolerance at lower doses than it 
reversed hydrocodone tolerance. It is possible that this difference occurred 
because hydrocodone produced a greater amount of tolerance than 
oxycodone. However, this is unlikely because the greatest tolerance was 
achieved using a multiple day oral oxycodone model and this tolerance was 
reversed by 0.5 mg/kg diazepam. Hydrocodone is also commonly administered 
to patients in tablets or solutions intended for oral use. We were not able to 
achieve tolerance when hydrocodone was given orally. This can be due to the 
fact that hydrocodone has been found to be less potent in certain measures of 
opioid effects (Zacny and Gutierrez, 2009). However, it is uncertain as to why 
we observed a greater amount of tolerance to repeated subcutaneous 
injections of hydrocodone compared to oxycodone yet no significant tolerance 
to hydrocodone given repeatedly orally. Further studies are needed to examine 
whether there is an important pharmacokinetic difference between oral dosing 
of oxycodone and hydrocodone. 
The interaction between benzodiazepines and opioids on antinociception has 
been reported in the literature but with disagreement. Doses of diazepam, up to 
5 mg/kg, were inactive in our warm water tail-withdrawal assays. Several 
studies reported antinociception with diazepam (Jiménez-Velázquez et al., 
2010, 2008; Sierralta and Miranda, 1992). This difference may lie in the 
different noxious stimuli used (chemical versus thermal) and route of 
administration (intracerebroventricular injection versus intraperitoneal). In our 
studies, there was no potentiation of oxycodone or hydrocodone induced 
antinociception with pretreatment doses of diazepam up to 0.5 mg/kg and 
2 mg/kg, respectively. Whereas in other studies, intrathecal administration of 
benzodiazepines were found to enhance opioid antinociception (Bergman et 
al., 1988; Rattan et al., 1991). In agreement with our studies, others found 
neither an antinociceptive effect of benzodiazepines nor a potentiation effect of 
benzodiazepines on opioid induced antinociception (Rodgers and Randall, 
1987; Mantegazza et al., 1982; Rosland et al., 1990). To our knowledge, 
benzodiazepines’ interaction with oxycodone or hydrocodone has not been 
previously investigated. 
In light of these results on antinociceptive tolerance, we tested the hypothesis 
that diazepam will have a similar effect in another paradigm of tolerance. We 
observed that oxycodone increased stimulatory activity in the locomotor 
activity assay. Marked tolerance was observed after repeated exposure to 
oxycodone over four days. Diazepam significantly reversed this marked 
tolerance. To rule out potentiation, we tested whether diazepam simply had an 
additive effect when combined with oxycodone. Diazepam did not potentiate 
acute oxycodone’s stimulatory effects nor did it have any stimulatory effects on 
its own. At this dose of diazepam, we did not detect either depressing or 
stimulatory effects. Diazepam is classified as a CNS depressant and has been 
shown to decrease locomotor activity (Spyraki and Papadopoulou, 1980). In 
certain cases (such as prolonged social isolation), low doses of diazepam have 
been shown either to be inactive or have a stimulatory effect, resulting in a 
bimodal dose response curve (Pinna et al., 2006). The similar reversal of 
tolerance seen in both antinociception and in locomotor activity suggest that 
diazepam acts on a mechanism of tolerance that is shared by both opioid-
induced effects. 
The precise mechanisms and neuronal circuitry involved remain to be 
elucidated. This tolerance-reversal effect could be responsible, in part, for the 
high incidence of polydrug use among opioid abusers. It has been suggested 
that opioid abusers occasionally combine the use of benzodiazepines with 
opioids to achieve a greater high (Jones et al., 2012). Whether this is simply an 
additive or synergistic effect is not clear and in a previous publication, we have 
suggested that compounds that act on GABA receptors increase the rewarding 
effects of opioid abuse by reducing tolerance (Hull et al., 2013). It has been 
theorized that both benzodiazepines and opioids produce a hyperpolarization 
of GABA interneurons which causes a reduction in the release of GABA which 
results in the disinhibition of dopaminergic neurons and an increase in 
extracellular dopamine in areas such as the striatum (Tan et al., 2011). The 
phenomenon of opioid-induced locomotion is due to mu opioid receptor-
mediated increases in striatal dopamine (DA) release (Johnson and Glick, 
1993; Kalivas and Duffy, 1987; Piepponen et al., 
1999). GABAergic interneurons also play an important role in opioid 
antinociception (Lau et al., 2014). This suggests a potential site of action that 
should be further examined. 
Our observations suggest this phenomenon is not due to the additive or 
synergistic effects of these CNS depressants but instead results from a reversal 
of tolerance. The result may be the same but the mechanism should be 
considered as new understandings of the tolerance mechanism will lead to new 
drug therapies such as tolerance-resistant analgesics. Similar reversal of opioid 
tolerance has been observed in models of respiratory depression and at the 
single cell level (Hill et al., 2016; Llorente et al., 2013). The reversant (reversing 
agent) in their studies was ethanol, which along with benzodiazepines, interacts 
with GABAAreceptors. 
The neurochemical mechanism of this reversal is likely due to diazepam’s 
action on GABAAreceptors. Our laboratory demonstrated that the diazepam 
reversal of morphine tolerance was fully inhibited by bicuculline, a 
GABAA antagonist, but not by phaclofen, a GABABantagonist. This was in 
contrast to ethanol as neither inhibitor fully reversed ethanol’s reversal or 
morphine tolerance until they were administered in combination (Hull et al., 
2013). Future studies should include determining whether the reversal of 
oxycodone and hydrocodone tolerance is due to diazepam’s effects on 
GABAA receptors, if any subtypes are significant for the effect, and the 
necessary intracellular pathways for this phenomenon. 
4. Conclusion 
Collectively, our findings demonstrate that the administration of diazepam, at 
doses that are not antinociceptive or have any motor effects, reverses both 
antinociceptive and locomotor tolerance to orally active opioids. These doses of 
diazepam did not potentiate the acute effects of these prescription opioids. The 
findings reported here suggest that individuals who are taking oral opioids for 
chronic pain relief and an anxiety agent such as diazepam need be cognizant 
of the risk of reversal of tolerance to opioids that could lead to unintentional 
overdose deaths. 
5. Experimental procedure 
5.1. Animals 
Male Swiss Webster mice (Harlan Laboratories, Indianapolis, IN) weighing 25–
30 g were housed five to a cage in animal care quarters and maintained at 
22 ± 2 °C on a 12-h light-dark cycle. Food and water were available ad libitum. 
The mice were brought to the test room (22 ± 2 °C, 12-h light-dark cycle), 
marked for identification, and allowed 18 h to recover from transport and 
handling. Protocols and procedures were approved by the Institutional Animal 
Care and Use Committee (IACUC) at Virginia Commonwealth University 
Medical Center and comply with the recommendations of the International 
Association for the Study of Pain (IASP). 
5.2. Drugs and chemicals 
Morphine sulfate, oxycodone HCl, hydrocodone bitartrate were obtained from 
the National Institutes of Health National Institute on Drug Abuse (Bethesda, 
MD) and were each dissolved in pyrogen-free isotonic saline (Hospira, Lake 
Forest, IL). Ethanol was obtained from AAPER Ethanol and Chemical Co. 
(Shelbyville, KY) and was diluted with pyrogen-free isotonic 
saline. Diazepam was obtained from Sigma-Aldrich Corporation (St Louis, MO, 
USA) and was dissolved in 45% hydroxypropyl beta-cyclodextrin (HPBCD). 
5.3. Antinociceptive testing 
Antinociception was assessed using the 56 °C warm water tail immersion test 
performed according to Coderre and Rollman (1983). Before injecting the mice, 
a baseline (control) latency was determined. Only mice with a control reaction 
time from 2 to 4 s were used. The test latency after opioid treatment was 
assessed at the peak time point of 20 min with a 10-s maximum cut-off time 
imposed to prevent tissue damage. Antinociception was quantified according to 
the method of Harris and Pierson (1964) as the percentage of maximum 
possible effect (%MPE), which was calculated as: %MPE = [(test 
latency − control latency)/(10 − control latency)] * 100. Percent MPE was 
calculated for each mouse. 
5.4. Tolerance studies 
A 7 h antinociceptive tolerance model for oxycodone and hydrocodone was 
developed. Mice were injected subcutaneously (s.c.) once every hour for 7 h 
(total of 7 injections) with an acute ED80 dose of the opioid (1.25 mg/kg for 
oxycodone and 6 mg/kg for hydrocodone, as previously determined). An hour 
after the final dose, mice were administered diazepam or vehicle 
by intraperitoneal injection and 30 min later were challenged with subcutaneous 
doses of oxycodone or hydrocodone to construct dose-response curves for 
calculation of ED50 values. The warm water tail immersion test was performed 
20 min after the injection of the challenge dose of opioid. 
For maximum tolerance to oral administration of oxycodone, the route of 
administration used by humans, a 4-day antinociceptive tolerance model was 
developed. Mice were orally gavaged with 256 mg/kg oxycodone twice a day 
(9 AM & 5 PM) on day 1, 2, and 3. On the fourth day, mice were gavaged only 
in the morning. A full 24 h after their last pretreatment dose, baseline latencies 
were recorded and immediately afterwards diazepam or vehicle was 
administered by intraperitoneal injection. 30 min later, mice were challenged 
with oral doses of oxycodone to construct dose-response curves for calculation 
of ED50 values. The warm water tail immersion test began 20 min after the 
administration of the challenge dose. 
5.5. Locomotor activity 
Spontaneous motor activity was assessed using activity chambers (Med 
Associates, St. Albans, VT). Each individual activity chamber has closeable 
doors and a ventilation system. The interior of the chamber consists of a 
27 × 27 cm Plexiglas enclosure that is wired with photo-beam cells connected 
to a computer console that counts the activity of the animal contained within the 
enclosure. For locomotor tolerance, a 4-day antinociceptive tolerance model 
was developed where mice were orally gavaged with 64 mg/kg oxycodone 
twice a day (9 AM & 5 PM) on day 1, 2, 3, and 4. On the fifth day, mice were 
habituated to the chamber for 30 min before any drug administration. 
Afterwards, mice were administered an intraperitoneal injection of vehicle or 
0.5 mg/kg diazepam and placed in home cage. 30 min later, mice were 
administered 64 mg/kg oxycodone by oral gavage. 10 min later, mice were 
placed in separate activity chambers. Ambulatory counts for spontaneous 
activity were obtained over a 40-min time period. 
5.6. Statistical analysis 
Opioid dose-response curves were generated for calculation of ED50 values 
using least-squares linear regression analysis followed by calculation of 95% 
confidence limits (95% CL) by the method of Bliss (1967). All data are 
represented as mean ± standard error of the mean. Locomotor data was 
analyzed using two-way analysis of variance (ANOVA) with factors for time, 
treatment, and their interactions with locomotor activity followed by Tukey’s 
post hoc analyses to determine statistical significance (Prism 6). Analyses were 
considered significant when p < 0.05. 
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